Alliance Pharma set to acquire Vamousse brand

5 December 2017 - Deborah Wilkes


Alliance Pharma is set to boost its consumer healthcare portfolio by acquiring worldwide rights to the head-lice treatment Vamousse from TyraTech and TYRU in a deal worth up to USD17.5 million.

Click tags below for more information on topics:

Alliance Pharma

Annual Subscription Holder?

Sign in to continue reading.

Sign In

Back to Industry News

Share this page: